142 related articles for article (PubMed ID: 10716641)
1. Multidentate hydroxypyridinonate ligands for Pu(IV) chelation in vivo: comparative efficacy and toxicity in mouse of ligands containing 1,2-HOPO or Me-3,2-HOPO.
Durbin PW; Kullgren B; Xu J; Raymond KN
Int J Radiat Biol; 2000 Feb; 76(2):199-214. PubMed ID: 10716641
[TBL] [Abstract][Full Text] [Related]
2. Specific sequestering agents for the actinides. 28. Synthesis and initial evaluation of multidentate 4-carbamoyl-3-hydroxyl-1-methyl-2(1H)-pyridinone ligands for in vivo plutonium(IV) chelation.
Xu J; Kullgren B; Durbin PW; Raymond KN
J Med Chem; 1995 Jul; 38(14):2606-14. PubMed ID: 7629800
[TBL] [Abstract][Full Text] [Related]
3. New agents for in vivo chelation of uranium(VI): efficacy and toxicity in mice of multidentate catecholate and hydroxypyridinonate ligands.
Durbin PW; Kullgren B; Xu J; Raymond KN
Health Phys; 1997 Jun; 72(6):865-79. PubMed ID: 9169929
[TBL] [Abstract][Full Text] [Related]
4. Synthesis and initial evaluation for in vivo chelation of Pu(IV) of a mixed octadentate spermine-based ligand containing 4-carbamoyl-3-hydroxy-1-methyl-2(1H)-pyridinone and 6-carbamoyl-1-hydroxy-2(1H)-pyridinone.
Xu J; Durbin PW; Kullgren B; Ebbe SN; Uhlir LC; Raymond KN
J Med Chem; 2002 Aug; 45(18):3963-71. PubMed ID: 12190318
[TBL] [Abstract][Full Text] [Related]
5. Specific sequestering agents for the actinides. 21. Synthesis and initial biological testing of octadentate mixed catecholate-hydroxypyridinonate ligands.
Uhlir LC; Durbin PW; Jeung N; Raymond KN
J Med Chem; 1993 Feb; 36(4):504-9. PubMed ID: 8386249
[TBL] [Abstract][Full Text] [Related]
6. Chelating agents for uranium(VI): 2. Efficacy and toxicity of tetradentate catecholate and hydroxypyridinonate ligands in mice.
Durbin PW; Kullgren B; Ebbe SN; Xu J; Raymond KN
Health Phys; 2000 May; 78(5):511-21. PubMed ID: 10772024
[TBL] [Abstract][Full Text] [Related]
7. Octadentate hydroxypyridinonate (HOPO) ligands for plutonium (i.v.): pharmacokinetics and oral efficacy.
Durbin PW; Kullgren B; Xu J; Raymond KN; Hengé-Napoli MH; Bailly T; Burgada R
Radiat Prot Dosimetry; 2003; 105(1-4):503-8. PubMed ID: 14527018
[TBL] [Abstract][Full Text] [Related]
8. 237Np: oxidation state in vivo and chelation by multidentate catecholate and hydroxypyridinonate ligands.
Durbin PW; Kullgren B; Xu J; Raymond KN; Allen PG; Bucher JJ; Edelstein NM; Shuh DK
Health Phys; 1998 Jul; 75(1):34-50. PubMed ID: 9645664
[TBL] [Abstract][Full Text] [Related]
9. Octadentate catecholamide ligands for Pu(IV) based on linear or preorganized molecular backbones.
Durbin PW; Kullgren B; Jeung N; Xu J; Rodgers SJ; Raymond KN
Hum Exp Toxicol; 1996 Apr; 15(4):352-60. PubMed ID: 8845226
[TBL] [Abstract][Full Text] [Related]
10. Competitive binding of Pu and Am with bone mineral and novel chelating agents.
Guilmette RA; Hakimi R; Durbin PW; Xu J; Raymond KN
Radiat Prot Dosimetry; 2003; 105(1-4):527-34. PubMed ID: 14527022
[TBL] [Abstract][Full Text] [Related]
11. Specific sequestering agents for the actinides. 16. Synthesis and initial biological testing of polydentate oxohydroxypyridinecarboxylate ligands.
White DL; Durbin PW; Jeung N; Raymond KN
J Med Chem; 1988 Jan; 31(1):11-8. PubMed ID: 2826783
[TBL] [Abstract][Full Text] [Related]
12. Biomimetic actinide chelators: an update on the preclinical development of the orally active hydroxypyridonate decorporation agents 3,4,3-LI(1,2-HOPO) and 5-LIO(Me-3,2-HOPO).
Abergel RJ; Durbin PW; Kullgren B; Ebbe SN; Xu J; Chang PY; Bunin DI; Blakely EA; Bjornstad KA; Rosen CJ; Shuh DK; Raymond KN
Health Phys; 2010 Sep; 99(3):401-7. PubMed ID: 20699704
[TBL] [Abstract][Full Text] [Related]
13. Chelation therapy by DFO-HOPO and 3,4,3-LIHOPO for injected Pu-238 and Am-241 in the rat: effect of dosage, time and mode of chelate administration.
Volf V; Burgada R; Raymond KN; Durbin PW
Int J Radiat Biol; 1996 Dec; 70(6):765-72. PubMed ID: 8980674
[TBL] [Abstract][Full Text] [Related]
14. The hexadentate hydroxypyridinonate TREN-(Me-3,2-HOPO) is a more orally active iron chelator than its bidentate analogue.
Yokel RA; Fredenburg AM; Durbin PW; Xu J; Rayens MK; Raymond KN
J Pharm Sci; 2000 Apr; 89(4):545-55. PubMed ID: 10737916
[TBL] [Abstract][Full Text] [Related]
15. Circulatory kinetics of intravenously injected 238Pu(IV) citrate and 14C-CaNa3-DTPA in mice: comparison with rat, dog, and reference man.
Durbin PW; Kullgren B; Schmidt CT
Health Phys; 1997 Feb; 72(2):222-35. PubMed ID: 9003707
[TBL] [Abstract][Full Text] [Related]
16. The efficacy of DFO-HOPO, DTPA-DX and DTPA for enhancing the excretion of plutonium and ameriicum from the rat.
Stradling GN; Gray SA; Moody JC; Hodgson A; Raymond KN; Durbin PW; Rodgers SJ; White DL; Turowski PN
Int J Radiat Biol; 1991 May; 59(5):1269-77. PubMed ID: 1675243
[TBL] [Abstract][Full Text] [Related]
17. Dose-dependent efficacy and safety toxicology of hydroxypyridinonate actinide decorporation agents in rodents: towards a safe and effective human dosing regimen.
Bunin DI; Chang PY; Doppalapudi RS; Riccio ES; An D; Jarvis EE; Kullgren B; Abergel RJ
Radiat Res; 2013 Feb; 179(2):171-82. PubMed ID: 23289385
[TBL] [Abstract][Full Text] [Related]
18. Lauriston S. Taylor Lecture: the quest for therapeutic actinide chelators.
Durbin PW
Health Phys; 2008 Nov; 95(5):465-92. PubMed ID: 18849679
[TBL] [Abstract][Full Text] [Related]
19. Solution thermodynamic stability of complexes formed with the octadentate hydroxypyridinonate ligand 3,4,3-LI(1,2-HOPO): a critical feature for efficient chelation of lanthanide(IV) and actinide(IV) ions.
Deblonde GJ; Sturzbecher-Hoehne M; Abergel RJ
Inorg Chem; 2013 Aug; 52(15):8805-11. PubMed ID: 23855806
[TBL] [Abstract][Full Text] [Related]
20. Chelation of 238Pu(IV) in vivo by 3,4,3-LICAM(C): effects of ligand methylation and pH.
Durbin PW; White DL; Jeung NL; Weitl FL; Uhlir LC; Jones ES; Bruenger FW; Raymond KN
Health Phys; 1989 Jun; 56(6):839-55. PubMed ID: 2722507
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
